| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
Shanghai Runda Medical Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥17.68 |
| 52 Week High | CN¥27.70 |
| 52 Week Low | CN¥11.20 |
| Beta | 0.38 |
| 1 Month Change | -4.02% |
| 3 Month Change | 17.48% |
| 1 Year Change | 48.45% |
| 3 Year Change | 52.55% |
| 5 Year Change | 74.02% |
| Change since IPO | -0.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| 603108 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | -4.6% | -0.9% | -0.8% |
| 1Y | 48.4% | -33.8% | -11.1% |
Return vs Industry: 603108 exceeded the CN Life Sciences industry which returned -33.8% over the past year.
Return vs Market: 603108 exceeded the CN Market which returned -11.1% over the past year.
Price Volatility
| 603108 volatility | |
|---|---|
| 603108 Average Weekly Movement | 9.2% |
| Life Sciences Industry Average Movement | 7.8% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in CN Market | 11.0% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 603108's share price has been volatile over the past 3 months.
Volatility Over Time: 603108's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 3,400 | Hui Liu | www.rundamedical.com |
Shanghai Runda Medical Technology Co., Ltd. provides integrated medical laboratory services in China. It offers platform supply, laboratory design/renovation, laboratory standardization, and information management system services; medical solutions to help healthcare professionals in the areas of biochemistry, diabetes, POCT, immunoassay analyzer, and molecular biology diagnosis; professional technical services; and logistic services.
Shanghai Runda Medical Technology Co., Ltd. Fundamentals Summary
| 603108 fundamental statistics | |
|---|---|
| Market cap | CN¥10.59b |
| Earnings (TTM) | CN¥214.86m |
| Revenue (TTM) | CN¥9.04b |
49.4x
P/E Ratio1.2x
P/S RatioIs 603108 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603108 income statement (TTM) | |
|---|---|
| Revenue | CN¥9.04b |
| Cost of Revenue | CN¥6.66b |
| Gross Profit | CN¥2.39b |
| Other Expenses | CN¥2.17b |
| Earnings | CN¥214.86m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.36 |
| Gross Margin | 26.39% |
| Net Profit Margin | 2.38% |
| Debt/Equity Ratio | 122.5% |
How did 603108 perform over the long term?
See historical performance and comparison